Treatment comparison RR 95% CI P-value
Naïve comparison: ORR of 70.4% for remestemcel-L-rknd versus 57.1% for ruxolitinib
ITC (unadjusted) 1.21 0.90-1.63 0.21
STC (adjusted) 1.13 0.83-1.63 0.45
ITC (unadjusted, grade III-IV aGVHD) 1.72 1.12-2.63 0.01
STC (adjusted, grade III-IV aGVHD) 1.58 1.02-2.33 0.04